Skip to main content
. 2015 Mar 10;112(7):1175–1182. doi: 10.1038/bjc.2015.62

Figure 3.

Figure 3

Survival in chemotherapy patients (who were included in the primary end point analysis n=41), classified as metabolic responders (⩾30% reduction in TGV) and non-responders (<30% fall in TGV).